Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 2;12(2):e00143-21. doi: 10.1128/mBio.00143-21

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Hilterbrand et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

PMC Copyright notice

FIG 4 — HSV-1 and VSVΔG-BHLD entry requires cellular cholesterol but not caveolin-1. C10 (A and B) and CHO-HVEM (C and D) cells were pretreated with a cholesterol-removal drug methyl-β-cyclodextrin (MβCD; 5 mM) and infected with HSV-1 (A and C) or VSVΔG-BHLD (B and D) at an MOI of 1. Infectivity was quantitated by flow cytometry at 6 h postinfection. (E) CHO-HVEM cells were transfected with a caveolin-1 siRNA (cav-1) or a scrambled control siRNA (scr) (both 50 pm) and infected with HSV-1 or VSVΔG-BHLD at an MOI of 1. Infectivity was quantitated by flow cytometry at 6 h postinfection. Significance was calculated using a two-tailed Student’s t test with Welch’s correction. *, P < 0.05; **, P < 0.01. (F) Western blot analyses, using antibody clone 4H312 (Santa Cruz Biotechnology), of caveolin-1 knockdown in CHO-HVEM cells (representative of three Western blots, one from each biological replicate). (G) Western blot analysis, using antibody clone 4H312 (Santa Cruz Biotechnology), of caveolin-1 levels in C10, CHO-HVEM, and 3T12 cells.